Tenaya Therapeutics (TNYA) Operating Leases (2021 - 2026)

Tenaya Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Operating Leases fell 30.79% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $7.0 million (down 30.79% YoY), while the FY2025 annual figure was $7.8 million, down 27.89% from the prior year.
• Operating Leases was $7.0 million for Q1 2026 at Tenaya Therapeutics, down from $7.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $13.1 million in Q2 2022 to a low of $7.0 million in Q1 2026.
• Historically, Operating Leases has averaged $10.1 million across 5 years, with a median of $10.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Operating Leases jumped 38.55% in 2025, then tumbled 30.79% in 2026.
• A 5-year view of Operating Leases shows it stood at $11.1 million in 2022, then retreated by 26.94% to $8.1 million in 2023, then soared by 33.62% to $10.8 million in 2024, then slipped by 27.89% to $7.8 million in 2025, then retreated by 10.35% to $7.0 million in 2026.
• The last three Operating Leases figures came in at $7.0 million (Q1 2026), $7.8 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.